Loading...
Market
Which age group will primarily receive FluMist nasal spray in the U.S. by end of 2024?
2
Resolution / Starting Odds
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
Evenly distributed • 25%
CDC reports or AstraZeneca's market analysis
Story
FDA Approves AstraZeneca's FluMist Nasal Spray, First Self-Administered Flu Vaccine
Sep 20, 2024, 08:06 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This marks the first time a flu vaccine can be administered at home without the need for a healthcare provider, making it the first of its kind. The vaccine, which is licensed for individuals aged 2 to 49, aims to increase accessibility and reduce barriers to flu vaccination. It will be available through third-party pharmacies, where users will complete a screening and eligibility assessment. The approval aligns with the FDA's broader efforts to expand consumer access to medications and reduce healthcare costs.
View original story
Similar markets
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
50+ years • 25%
2-12 years • 25%
13-24 years • 25%
25-35 years • 25%
36-49 years • 25%
2-12 years • 25%
13-24 years • 25%
25-34 years • 25%
35-49 years • 25%
2-12 years • 25%
13-29 years • 25%
30-49 years • 25%
Equal uptake across all age groups • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
Evenly distributed • 25%
2-18 years • 25%
19-29 years • 25%
30-49 years • 25%
All age groups equally • 25%
2-12 years • 25%
13-24 years • 25%
25-34 years • 25%
35-49 years • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Children (6 months to 11 years) • 25%
Adolescents (12 to 17 years) • 25%
Adults (18 to 64 years) • 25%
Seniors (65 years and older) • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%